Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA ...

A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using artificial-intelligence software that recreates his widely recognized gravelly voice ...

Stephen Hawking would have turned 83 years old. Unfortunately, the world-renowned physicist passed away in 2018. Before his ...

Biopharma innovator Alchemab Therapeutics, whose labs are in Cambridge UK, is collaborating with multinational pharma giant ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...

UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.